Abstract
Background Teratogenic viruses are viruses than can cross the placenta and infect a growing foetus, resulting in malformations and birth defects. Some of the commonly known teratogenic viruses include cytomegalovirus (CMV), rubella, herpes simplex and varicella zoster (VZV) viruses. Most birth defects associated with these infections affect the central nervous system and sensory organs leading to symptoms that include mental retardation, hearing loss and blindness. The economic burden caused by congenital birth defects is high, as many affected children require special care, therapeutic and educational services. Despite the risk posed by teratogenic viruses during pregnancy, there is no national screening for active CMV, Rubella or VZV infection during pregnancy in Botswana and most African countries. Furthermore, data on the seroprevalence of these viruses among women of childbearing age is limited.
Methods and setting This cross-section study used eighty-nine (89) residual plasma samples from Scottish Livingstone Hospital Laboratory in Molepolole-Botswana. Samples were from women between the ages 15-49 years. Samples were tested for antibodies against rubella, VZV and CMV using enzyme linked immunosorbent assay.
Results Our results show a high seroprevalence of rubella IgG antibodies (97%), even though a small proportion (3%) of women are still susceptible. There was also a high seroprevalence of CMV IgG (100%) which was accompanied by an equally high CMV IgM of 98%. Seroprevalence of VZV IgG was low (63%) and 3% of the samples showed active VZV infection.
Conclusions Teratogenic viruses are a concern in the population. This calls for preventative measures which include prompt screening and vaccination of susceptible eligible women to prevent congenital abnormalities in children.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Department of Tertiary Education Financing (DTEF)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Ministry of Health Research and development division (MoH HRDC) gave ethical approval for this work. Also Ethics committee/IRB of University of Botswana gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
